Satsuma Pharmaceuticals, Inc. (STSA)
Satsuma Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $1.10, up 0.00% on the session, giving a market capitalisation of $36.5M. On trailing twelve-month figures it carries a trailing P/E of -0.51, a net margin of 0.0%. Its beta of 0.10 implies it has historically moved less than the broad market.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. is most often compared with the following Healthcare names: